Tavaborole

Tavaborole
Clinical data
Trade names	Kerydin
Other names	AN2690
AHFS/Drugs.com	Monograph
MedlinePlus	a614049
Routes of; administration	Topical
ATC code	D01AE24 (WHO) ;
Legal status
Legal status	US: ℞-only; In general: ℞ (Prescription only);
Identifiers
	IUPAC name 5-Fluoro-2,1-benzoxaborol-1(3H)-ol;
CAS Number	174671-46-6;
PubChem CID	11499245;
DrugBank	DB09041;
ChemSpider	9674047;
UNII	K124A4EUQ3;
KEGG	D10169;
CompTox Dashboard (EPA)	DTXSID00169888 ;
ECHA InfoCard	100.218.130
Chemical and physical data
Formula	C7H6BFO2
Molar mass	151.93 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES B1(C2=C(CO1)C=C(C=C2)F)O;
	InChI InChI=1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2; Key:LFQDNHWZDQTITF-UHFFFAOYSA-N;

Tavaborole, sold under the brand name Kerydin, is a topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed with a complete clearance rate of 6-7% and partial clearance rate of 23-24% in individuals whose “infection border does not reach the cuticle at the base of the large toenail.” Tavaborole was approved by the US FDA in July 2014. The medication inhibits an essential fungal enzyme, leucyl-tRNA synthetase, that is required for protein synthesis. The inhibition of protein synthesis leads to termination of cell growth and then cell death, eliminating the fungal infection.